*LiquidScan®

ISOLATE RARE CELLS AND EXOSOMES – CTCs, TROPHOBLASTS, EVs

BioFluidica has created LiquidScan® as a unique fully automated system for isolating and enriching rare cells and exosomes from liquid biopsy samples. The system uses a microfluidic chip surfaced with antibodies targeting biomarkers of interest, creating the future of liquid biopsy.

LIQUIDSCAN® WORKFLOW

THE *LIQUIDSCAN SYSTEM

  • LiquidScan Microfluidic Chip Processing Module

  • B³ BioFluidica Blood Collection Tube

  • LiquidScan Reagent Kit
    (with LiquidScan Microfluidic Chips surfaced with antibodies)

  • LiquidScan Software

  • LiquidScan installs on a Hamilton Microlab STARlet or STAR liquid handling robot
    (Contact us
    regarding pre-owned, new or adding LiquidScan to one you already have)

*For Research Use Only

Consumables

LIQUIDSCAN REAGENT KITS

  • Reagent plate with contents ready to process 4 or 8 microfluidic chips

  • Microfluidic chips (4 or 8):

    • Antibody-surfaced sinusoidal chips for rare-cell capture or,
    • Antibody-surfaced pillar chips for exosome subpopulation capture
  • Sample tubes (8)

  • Waste tubes or re-process sample tubes (8)

B³ BLOOD COLLECTION TUBE

  • The B³ Blood Collection Tube allows for collecting whole blood by a phlebotomist and room temperature shipping.

  • The B³ Blood Collection Tube is a standard blood draw EDTA purple-capped vacuum collection tube containing 1 ml of BioFluidica Blood Buffer.
    (BioFluidica Blood Buffer inhibits micro-clotting and allows for 24-hour room temperature shipping.)

  • B³ Blood Collection Tubes can be ordered in bulk lots separate from Reagent Kits.

Schedule a consultation with our research team to discuss your specific needs.

*LiquidScan is for Research Use Only

ABOUT BIOFLUIDICA

BioFluidica is a privately held biotechnology and liquid biopsy company. We have developed a revolutionary liquid biopsy platform allowing for the isolation and analysis of all liquid biopsy biomarkers, including rare cells, extracellular vesicles (EVs; exosomes), and cfDNA, on one fully automated platform. The Biofluidica platform has been clinically tested on nine different cancer and prenatal patient samples and is currently used for a large variety of research applications to advance the field of liquid biopsy. The ultralow sensitivity expands the capability of current liquid biopsy applications. We are expert consultants in exosome isolation, fetal cell (trophoblast)  isolation, CTC isolation, and next-generation liquid biopsy. We develop and launch innovative scientific instruments, reagents, and software systems designed to provide exceptional value for scientists, clinicians, and patients.